Ipragliflozin

	File:Ipragliflozin.svg
Systematic (IUPAC) name
	(1S)-1,5-Anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol
Clinical data
Trade names	Suglat
Identifiers
PubChem	CID: 10453870
ChemSpider	8629286
KEGG	D10196
ChEMBL	CHEMBL2018096
Chemical data
Formula	C21H21FO5S
Molecular mass	404.45 g/mol
	SMILES S1C(=CC2=C1C=CC=C2)CC=2C=C(C=CC2F)[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](O2)CO ;
	InChI InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1 COPY ; Key:AHFWIQIYAXSLBA-RQXATKFSSA-N ;

Ipragliflozin (Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. It was approved for use in Japan in 2014.^[1]

Ipragliflozin is an SGLT2 inhibitor.^[2]

References

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.